ATE160818T1 - Zusammensetzungen und verfahren zur identifizierung von molekülen mit biologischer wirksamkeit - Google Patents

Zusammensetzungen und verfahren zur identifizierung von molekülen mit biologischer wirksamkeit

Info

Publication number
ATE160818T1
ATE160818T1 AT91910915T AT91910915T ATE160818T1 AT E160818 T1 ATE160818 T1 AT E160818T1 AT 91910915 T AT91910915 T AT 91910915T AT 91910915 T AT91910915 T AT 91910915T AT E160818 T1 ATE160818 T1 AT E160818T1
Authority
AT
Austria
Prior art keywords
compositions
methods
biological activity
identifying molecules
molecules
Prior art date
Application number
AT91910915T
Other languages
English (en)
Inventor
James J Devlin
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE160818T1 publication Critical patent/ATE160818T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT91910915T 1990-06-01 1991-05-13 Zusammensetzungen und verfahren zur identifizierung von molekülen mit biologischer wirksamkeit ATE160818T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53318090A 1990-06-01 1990-06-01

Publications (1)

Publication Number Publication Date
ATE160818T1 true ATE160818T1 (de) 1997-12-15

Family

ID=24124831

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91910915T ATE160818T1 (de) 1990-06-01 1991-05-13 Zusammensetzungen und verfahren zur identifizierung von molekülen mit biologischer wirksamkeit

Country Status (10)

Country Link
EP (1) EP0600866B1 (de)
JP (1) JPH05507700A (de)
AT (1) ATE160818T1 (de)
AU (2) AU8081491A (de)
CA (1) CA2084307A1 (de)
DE (1) DE69128362T2 (de)
DK (1) DK0600866T3 (de)
ES (1) ES2109945T3 (de)
GR (1) GR3025596T3 (de)
WO (1) WO1991018980A1 (de)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US7413537B2 (en) 1989-09-01 2008-08-19 Dyax Corp. Directed evolution of disulfide-bonded micro-proteins
US5747334A (en) * 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
DE69233769D1 (de) 1991-03-01 2009-09-24 Dyax Corp Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
DE69229222D1 (de) * 1991-03-07 1999-06-24 Bradbury Auswahl spezifischer proteine durch ein biologisches verfahren
ATE414768T1 (de) * 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) * 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
WO1993007169A1 (en) * 1991-10-04 1993-04-15 Chiron Corporation Peptide inhibitors of platelet adhesion
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5733731A (en) * 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
EP0663953B1 (de) * 1992-09-04 2001-12-05 The Scripps Research Institute Phagemiden die einen oberflächenrezeptor und ein heterologes oberflächenprotein co-exprimieren
AU6235294A (en) 1993-02-02 1994-08-29 Scripps Research Institute, The Methods for producing polypeptide binding sites
IT1270939B (it) * 1993-05-11 1997-05-26 Angeletti P Ist Richerche Bio Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.
JPH08510325A (ja) * 1993-05-28 1996-10-29 カイロン コーポレイション 生物学的に活性なペプチド配列の選択方法
IT1261693B (it) * 1993-06-01 1996-05-29 Angeletti P Ist Richerche Bio Metodologia per la produzione di fagi filamentosi che espongono sulla superficie del capside peptidi capaci di legare la biotina, e fagi filamentosi e peptidi cosi' ottenibili.
CA2173990A1 (en) * 1993-10-12 1995-04-20 Narasinga Rao A library of glyco-peptides useful for identification of cell adhesion inhibitors
US5922545A (en) * 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5516637A (en) * 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
EP0789783B1 (de) * 1994-09-21 2002-05-08 Cytogen Corporation Antigen bindende peptide (abtides) aus peptidbibliotheken
US5885577A (en) * 1994-09-21 1999-03-23 Cytogen Corporation Antigen binding peptides (abtides) from peptide libraries
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
CA2258125C (en) 1996-06-14 2010-11-23 Meiji Milk Products Co., Ltd. T-cell epitope peptides
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
EP1254369B1 (de) 2000-02-08 2010-10-06 Sangamo BioSciences, Inc. Zellen zur entdeckung von medikamenten
DK1360500T3 (da) 2000-04-14 2010-05-25 Genencor Int Fremgangsmåde til selektiv målretning
US7129326B2 (en) 2000-04-14 2006-10-31 Genencor International, Inc. Methods for selective targeting
WO2001084149A2 (en) 2000-04-29 2001-11-08 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
EP1414491A4 (de) 2001-07-09 2005-07-06 Elan Pharm Inc Verfahren zur hemmung der toxizität von amyloid
WO2009095742A1 (en) 2008-01-31 2009-08-06 Cellectis New i-crei derived single-chain meganuclease and uses thereof
CA2481504C (en) 2002-04-08 2011-08-23 Pioneer Hi-Bred International, Inc. Enhanced silk exsertion under stress
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
GB2392723B (en) 2002-09-04 2005-01-12 Bioinvent Int Ab Screening methods
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
BR0316737A (pt) 2002-11-27 2005-12-13 Irm Llc Métodos e composições para induzir apoptose em células cancerosas
WO2004067753A2 (en) 2003-01-28 2004-08-12 Cellectis Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof.
NZ567324A (en) 2003-02-01 2009-08-28 Wyeth Corp Active immunization to generate antibodies to soluble A-beta
CA2526900C (en) 2003-05-19 2015-11-24 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in lewy body disease
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
US20060162014A1 (en) 2003-07-07 2006-07-20 Jaffe Eileen K Alternate morpheeins of allosteric proteins as a target for the development of bioactive molecules
US8153410B2 (en) 2003-07-07 2012-04-10 Fox Chase Cancer Center Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules
SI1701968T1 (sl) 2003-12-17 2015-08-31 Wyeth Llc Imunogeni konjugati peptidnih nosilcev in postopek izdelave istih
UA84728C2 (ru) 2003-12-17 2008-11-25 Вайет ПРОЦЕСС ОБРАЗОВАНИЯ ИММУНОГЕННОГО КОНЪЮГАТА, ИММУНОГЕННЫЙ КОНЪЮГАТ БЕЛКА Aβ С БЕЛКОМ-НОСИТЕЛЕМ И ИММУНОЛОГИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ЕГО СОДЕРЖИТ
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
US7572600B2 (en) 2004-08-04 2009-08-11 Chemocentryx, Inc. Enzymatic activities in chemokine-mediated inflammation
MX2007001679A (es) 2004-08-09 2007-05-23 Elan Pharm Inc Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
CA2597411C (en) 2005-02-14 2014-08-12 University Of Iowa Research Foundation Use of complement factor h polymorphisms in treatment and diagnosis of age-related macular degeneration
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
PE20110071A1 (es) 2005-05-19 2011-01-31 Centocor Inc Anticuerpos anti-mcp-1, composiciones y metodos
PT2452694T (pt) 2005-06-30 2019-02-21 Janssen Biotech Inc Anticorpos anti-il-23, composições, métodos e utilizações
EP1910837B1 (de) 2005-07-01 2012-03-14 Arbor Vita Corporation Verfahren und zusammensetzungen zur diagnose und behandlung von grippe
US8193328B2 (en) 2005-09-08 2012-06-05 Philadelphia Health & Education Corporation Identification of modulators of serine protease inhibitor Kazal and their use as anti-cancer and anti-viral agents
WO2007053358A2 (en) 2005-10-28 2007-05-10 Praecis Pharmaceuticals, Inc. Methods for identifying compounds of interest using encoded libraries
EA035459B1 (ru) 2005-12-29 2020-06-19 Сентокор, Инк. Антитело против il-23p19
US8357781B2 (en) 2006-06-01 2013-01-22 Janssen Alzheimer Immunotherapy Neuroactive fragments of APP
ES2546863T3 (es) 2007-02-23 2015-09-29 Prothena Biosciences Limited Prevención y tratamiento de enfermedad sinucleinopática y amiloidogénica
JP5558834B2 (ja) 2007-02-23 2014-07-23 ヤンセン アルツハイマー イミュノセラピー シヌクレイノパチーおよびアミロイド形成疾患（ａｍｙｌｏｉｄｏｇｅｎｉｃｄｉｓｅａｓｅ）の予防および処置
EP2182943B1 (de) 2007-07-23 2016-10-26 Janssen Biotech, Inc. Verfahren und zusammensetzungen zur behandlung von fibrosebedingten erkrankungen mit il-17-antagonisten
BRPI0819743A2 (pt) 2007-11-20 2014-10-07 Pioneer Hi Bred Int Ácido nucléico isolado, cassete de expressão, célula hospedeira, planta transgênica, semente transgênica, método para modular a resposta de etileno em uma planta, proteína isolada
RU2559782C2 (ru) 2007-12-17 2015-08-10 Марфл Аб Набор для детекции спор, происходящих из микобактерий
ES2544679T3 (es) 2007-12-28 2015-09-02 Prothena Biosciences Limited Tratamiento y profilaxis de la amiloidosis
AR073060A1 (es) 2008-08-14 2010-10-13 Arana Therapeutic Ltd Anticuerpos anti-il-12/il-23
MX2011001900A (es) 2008-08-18 2011-08-17 Seoul Nat Univ Ind Foundation Metodo para controlar metastasis de cancer o migracion de celulas de cancer modulando el nivel celular de lisil-tarn sintetasa.
BRPI0919881B1 (pt) 2008-10-31 2021-09-08 Centocor Ortho Biotech Inc Proteína de arcabouço e seu método de geração, biblioteca e seu método de construção, molécula de ácido nucleico, vetor de ácido nucleico, célula hospedeira, composição, dispositivo médico e artigo de fabricação
BRPI1008532B1 (pt) 2009-02-12 2021-12-14 Janssen Biotech, Inc Arcabouço de proteína isolada, método para construção de uma biblioteca de arcabouço de proteína isolada, molécula de ácido nucleico isolada, vetor de ácido nucleico isolado, célula hospedeira de bactéria ou fungo, composição, dispositivo médico e artigo de manufatura para uso farmacêutico ou de diagnóstico em seres humanos
US8716553B2 (en) 2009-03-02 2014-05-06 Pioneer Hi Bred International Inc NAC transcriptional activators involved in abiotic stress tolerance
JP6059014B2 (ja) 2009-06-19 2017-01-11 アリゾナ ボード オブ リージェンツ ア ボディー コーポレート アクティング オン ビハーフ オブ アリゾナ ステイト ユニバーシティＡＲＩＺＯＮＡ ＢＯＡＲＤ ＯＦ ＲＥＧＥＮＴＳ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ ａｃｔｉｎｇ ｏｎ ｂｅｈａｌｆ ｏｆ ＡＲＩＺＯＮＡ ＳＴＡＴＥ ＵＮＩＶＥＲＳＩＴＹ 試料の構成成分の検出において使用されるデバイスを製造する方法およびペプチドアレイ
US20110035843A1 (en) 2009-08-05 2011-02-10 Pioneer Hi-Bred International, Inc. Novel eto1 genes and use of same for reduced ethylene and improved stress tolerance in plants
MX2012006397A (es) 2009-12-02 2012-11-30 Amgen Inc PROTEINAS DE ENLACE QUE ENLAZAN A FGFR1C HUMANO, ß-KLOTHO HUMANA Y TANTO FGFR1C HUMANO COMO ß-KLOTHO HUMANA.
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
ES2713873T3 (es) 2010-04-16 2019-05-24 Nuevolution As Complejos bifuncionales y métodos para hacer y utilizar tales complejos
WO2012162514A2 (en) 2011-05-26 2012-11-29 Regents Of The University Of Michigan Epigenetic co-repressors of the gamma-globin gene and methods of using same
GB201116364D0 (en) 2011-09-22 2011-11-02 Bioinvent Int Ab Screening methods and uses thereof
EP2758775B1 (de) 2011-09-22 2017-08-16 Medicinal Bioconvergence Research Center Neue verwendung von leucyl-trna-synthetase
US9678062B2 (en) 2011-09-23 2017-06-13 University Of Louisville Research Foundation, Inc. Methods and compositions for expanding cells and improving engraftment
KR101398079B1 (ko) 2011-10-10 2014-05-27 재단법인 의약바이오컨버젼스연구단 글리실-티알엔에이 합성효소 및 캐드헤린을 이용한 암 예방 또는 치료제의 스크리닝 방법
CN103906835A (zh) 2011-10-25 2014-07-02 先锋国际良种公司 改变植物细胞壁组成以改善生物燃料生产和青贮饲料可消化性的方法
WO2014152507A2 (en) 2013-03-15 2014-09-25 Pioneer Hi-Bred International, Inc. Modulation of acc deaminase expression
CN105308073B (zh) 2013-06-14 2019-08-13 加利福尼亚太平洋生物科学股份有限公司 双生物素化标签
RS63295B1 (sr) 2013-12-24 2022-06-30 Janssen Pharmaceutica Nv Anti-vista antitela i fragmenti
AU2016251501A1 (en) 2015-04-20 2017-10-19 F. Hoffmann-La Roche Ag Specific peptide binders to proteins identified via systemic discovery, maturation and extension process
CN107922497B (zh) 2015-06-24 2022-04-12 詹森药业有限公司 抗vista抗体和片段
DK3341725T3 (da) 2015-08-25 2021-09-06 Prothena Biosciences Ltd Fremgangsmåder til detektering af phosphoryleret alpha-synuklein
US10758886B2 (en) 2015-09-14 2020-09-01 Arizona Board Of Regents On Behalf Of Arizona State University Conditioned surfaces for in situ molecular array synthesis
CN109069626A (zh) 2016-02-12 2018-12-21 詹森药业有限公司 抗-vista(b7h5)抗体
MA44510A (fr) 2016-03-29 2021-03-31 Janssen Biotech Inc Methode de traitement du psoriasis avec dosage intervalle augmenté d'anticorps anti-il12 et/ou -23
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
KR20190020106A (ko) 2016-06-20 2019-02-27 헬스텔 인크. 자가면역 질환의 차별적 진단 방법
WO2017223117A1 (en) 2016-06-20 2017-12-28 Healthtell Inc. Methods for diagnosis and treatment of autoimmune diseases
PT3482210T (pt) 2016-07-06 2021-07-28 Prothena Biosciences Ltd Ensaio para detetar alfa-sinucleína total e fosforilada s129
WO2018014038A1 (en) 2016-07-15 2018-01-18 Poseida Therapeutics, Inc. Chimeric antigen receptors and methods for use
WO2018014039A1 (en) 2016-07-15 2018-01-18 Poseida Therapeutics, Inc. Chimeric antigen receptors (cars) specific for muc1 and methods for their use
DK3519049T3 (da) 2016-09-30 2026-01-12 Janssen Biotech Inc Sikker og effektiv fremgangsmåde til behandling af psoriasis med specifikt anti-il23-antistof
CN110168370A (zh) 2016-11-11 2019-08-23 健康之语公司 用于鉴定候选生物标志物的方法
KR20240065333A (ko) 2016-11-16 2024-05-14 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 건선을 치료하는 방법
EP3573658A4 (de) 2017-01-30 2021-07-21 Janssen Biotech, Inc. Anti-tnf-antikörper, zusammensetzungen und verfahren zur behandlung von aktiver psoriatischer arthritis
KR20190115042A (ko) 2017-02-07 2019-10-10 얀센 바이오테크 인코포레이티드 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
WO2018169948A1 (en) 2017-03-13 2018-09-20 Poseida Therapeutics, Inc. Compositions and methods for selective elimination and replacement of hematopoietic stem cells
WO2018202850A1 (en) 2017-05-05 2018-11-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Microtubule-targeting drugs as immune checkpoint inhibitors and methods of screening novel immune checkpoint inhibitors for the treatment of cancers and infectious diseases
EP3679145A2 (de) 2017-09-08 2020-07-15 Poseida Therapeutics, Inc. Zusammensetzungen und verfahren für durch chimären ligandenrezeptor (clr) vermittelte bedingte genexpression
WO2019055618A1 (en) 2017-09-15 2019-03-21 Arizona Board Of Regents On Behalf Of Arizona State University METHODS OF CLASSIFYING RESPONSES TO ANTICANCER IMMUNOTHERAPY
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
CN112218885B (zh) 2017-12-20 2024-06-18 波赛达治疗公司 Vcar组合物和使用方法
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
IL276896B2 (en) 2018-03-05 2024-06-01 Janssen Biotech Inc Methods of treating crohn's disease with anti-il23 specific antibody
JP2021523138A (ja) 2018-05-11 2021-09-02 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ−２３抗体を使用してうつを治療する方法
WO2020016838A2 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
BR112021009287A2 (pt) 2018-11-20 2021-10-26 Janssen Biotech, Inc. Método seguro e eficaz para tratar psoríase com anticorpo específico anti-il-23
EP3897722A4 (de) 2018-12-18 2022-09-14 Janssen Biotech, Inc. Sichere und wirksame methode zur behandlung von lupus mit anti-il12/il23-antikörper
AU2019401282A1 (en) 2018-12-20 2021-07-15 Poseida Therapeutics, Inc. Nanotransposon compositions and methods of use
CA3133383A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
WO2020183269A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
WO2020183271A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
MA55383A (fr) 2019-03-18 2022-01-26 Janssen Biotech Inc Méthode de traitement du psoriasis chez des sujets pédiatriques avec un anticorps anti-il12/il23
CN113874392B (zh) 2019-03-28 2025-10-21 丹尼斯科美国公司 工程化抗体
CA3136119A1 (en) 2019-04-10 2020-10-15 University Of Utah Research Foundation Htra1 modulation for treatment of amd
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
MX2021014882A (es) 2019-06-03 2022-03-25 Janssen Biotech Inc Anticuerpos anti-tnf, composiciones y métodos para el tratamiento de la espondilitis anquilosante activa.
MA56015A (fr) 2019-06-03 2022-04-06 Janssen Biotech Inc Compositions d'anticorps anti-tnf et méthodes pour le traitement de l'arthrite psoriasique
AU2020288749A1 (en) 2019-06-04 2022-02-03 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-IL23 specific antibody
CN114761424B (zh) 2019-09-05 2025-09-19 波赛达治疗公司 同种异体细胞组合物和使用方法
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
JP7743407B2 (ja) 2019-12-20 2025-09-24 ポセイダ セラピューティクス，インコーポレイティド 抗Ｍｕｃ１組成物及び使用方法
US20230121433A1 (en) 2020-03-11 2023-04-20 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
CN115996747A (zh) 2020-04-14 2023-04-21 波赛达治疗公司 用于治疗癌症的组合物和方法
CA3181949A1 (en) 2020-05-05 2021-11-11 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
CN115768466A (zh) 2020-05-21 2023-03-07 詹森生物科技公司 用抗IL-23和TNFα抗体的联合疗法治疗炎性肠病的方法
WO2022087148A1 (en) 2020-10-21 2022-04-28 Poseida Therapeutics, Inc. Compositions and methods for delivery of nucleic acids
CN117957251A (zh) 2021-07-09 2024-04-30 詹森生物科技公司 用于制备抗tnf抗体组合物的制造方法
WO2023281462A1 (en) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
CA3233506A1 (en) 2021-10-04 2023-04-13 Joseph S. LUCAS Transposon compositions and methods of use thereof
KR20240099352A (ko) 2021-10-29 2024-06-28 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 크론병을 치료하는 방법
US20250099383A1 (en) 2022-01-21 2025-03-27 Poseida Therapeutics, Inc. Compositions and methods for delivery of nucleic acids
CN119698430A (zh) 2022-03-30 2025-03-25 詹森生物科技公司 用il-23特异性抗体治疗轻度至中度银屑病的方法
US20230374122A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody
IL321059A (en) 2022-11-22 2025-07-01 Janssen Biotech Inc Method for treating ulcerative colitis with a specific anti-IL23 antibody
WO2025160432A1 (en) 2024-01-26 2025-07-31 Poseida Therapeutics, Inc. Methods and compositions for enhancing in vivo persistence and potency of cell therapy
WO2025262604A1 (en) 2024-06-17 2025-12-26 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
WO2026003761A1 (en) 2024-06-27 2026-01-02 Janssen Biotech, Inc. Methods of treating ulcerative colits with anti-il23 specific antibody

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713366A (en) * 1985-12-04 1987-12-15 The Ohio State University Research Foundation Antigenic modification of polypeptides
EP1541682A3 (de) * 1988-09-02 2005-07-06 Dyax Corp. Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods

Also Published As

Publication number Publication date
GR3025596T3 (en) 1998-03-31
DK0600866T3 (da) 1998-03-09
DE69128362T2 (de) 1998-05-20
JPH05507700A (ja) 1993-11-04
AU8081491A (en) 1991-12-31
WO1991018980A1 (en) 1991-12-12
EP0600866B1 (de) 1997-12-03
AU3310595A (en) 1996-02-22
AU699732B2 (en) 1998-12-10
DE69128362D1 (de) 1998-01-15
ES2109945T3 (es) 1998-02-01
EP0600866A1 (de) 1994-06-15
CA2084307A1 (en) 1991-12-02

Similar Documents

Publication Publication Date Title
ATE160818T1 (de) Zusammensetzungen und verfahren zur identifizierung von molekülen mit biologischer wirksamkeit
DE68903482D1 (de) Zement, verfahren zur herstellung dieses zements und verfahren zur herstellung von produkten mit diesem zement.
DE68923319D1 (de) Fluorkohlenstoff- Membranen und Verfahren zur Herstellung von Fluorkohlenstoff-Membranen.
DE58908382D1 (de) Verfahren und Vorrichtung zur Herstellung von Borstenwaren.
DE69201589D1 (de) Wachsumhüllte Partikel und Verfahren zur Herstellung derselben.
DE68912336D1 (de) Hydrophobe proteinmikroteilchen und verfahren zur herstellung.
DE69126762D1 (de) Biologisches Verfahren zur Herstellung von Alpha-Hydroxyamid und Alpha-Hydroxysäure
DE3886626D1 (de) Verfahren und Zusammenstellung zur Darstellung von Pyrithionen mit reduzierter Dekoloration.
DE59200764D1 (de) Verfahren und Einrichtung zur Aufbereitung oder Herstellung von Kunststoffen.
DE69015391D1 (de) Verfahren zur Herstellung von Kunststoffteilchen.
DE68912655D1 (de) Verfahren zur Herstellung von Decabromediphenylalkanen und Decabromdiphenylethan.
ATE111439T1 (de) Verfahren zur herstellung von levodopa.
DE68917457D1 (de) Deodorant und verfahren zur herstellung.
DE3668765D1 (de) Verfahren zur herstellung von borstenwaren und danach hergestellte borstenwaren.
DE59101232D1 (de) Verfahren und Mittel zur Herstellung von Bohrungen.
DE59002322D1 (de) Verfahren zur herstellung von 1,1,1,3,3,3-hexafluorpropan und 2-chlor-1,1,1,3,3,3-hexafluorpropan.
DE69109427D1 (de) Blockcopolymerdispersionen und Verfahren zur Herstellung von Blockcopolymerdispersionen.
DE69016245D1 (de) Artikel zur Gewebekonditionierung.
DE69014109D1 (de) Verfahren zur bräunung mit mikrowellen und so hergestelltes produkt.
DE68917154D1 (de) C-terminus-amidierungsenzym-zusammensetzung, verfahren zur herstellung und verwendung.
DE59001713D1 (de) Verfahren und anlage zur herstellung von holzspanplatten und aehnlichen plattenwerkstoffen.
DE69115296D1 (de) Verfahren zur eigenschaftsverbesserung von beschichteten, verstaerkten thermoplastartikeln und damit hergestellte produkte.
DE59106553D1 (de) Verfahren zur herstellung von chlorfluornitrobenzolen und difluornitrobenzolen.
DE59101473D1 (de) Verfahren zur Herstellung von N-aryl-substituierten 2-Aminoalkyl-2-hydroxy-alkylaminen und N-arylsubstituierten Piperazinen.
DE68911148D1 (de) Zusammensetzungen und verfahren zur herstellung von schaumkunststoffen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee